Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press85110.17650/1726-9776-2018-14-2-177-182CONGRESSES AND CONFERENCESСЪЕЗДЫ И КОНФЕРЕНЦИИ33rd Annual Congress of the European Association of Urology in 2018: Review of oncological topics33-й ежегодный конгресс Eвропейской ассоциации урологов в 2018 г.: обзор онкоурологических тематикhttps://orcid.org/0000-0002-3172-2909MarkovaA. S.МарковаА. С.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

Анна Сергеевна Маркова 

115478 Москва, Каширское шоссе, 24

Mark-an1@yandex.ruN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России300620181421771820607201806072018https://oncourology.abvpress.ru/oncur/article/view/851

From 16 th to 20 th of March, 2018, the 33 rd Annual Congress of the European Association of Urology took place in Copenhagen. Doctors from 78 countries participated in the event. 4,381 abstracts were submitted, 1,338 of which were selected for poster sessions. Prostate cancer, kidney cancer, and bladder cancer were the most studied topics and constituted about a half of all accepted abstracts. In this article, a review of the most significant and interesting reports on cancer urology from the EAU Congress in 2018 is presented.

16–20 марта 2018 г. в Копенгагене состоялся 33-й ежегодный конгресс Eвропейской ассоциации урологов, в котором приняли участие врачи из 78 стран мира. На конгресс был направлен 4381 тезис, 1338 из которых отобраны для докладов в рамках постерных сессий. Рак предстательной железы, рак почки и рак мочевого пузыря – самые исследуемые темы, которые составили около половины всех принятых тезисов. Статья посвящена обзору наиболее значимых и запоминающихся докладов, представленных на конгрессе EAU в 2018 г. по онкоурологическим заболеваниям.

the European Association of Urologyprostate cancerkidney cancerbladder cancerEвропейская ассоциация урологоврак предстательной железырак почкирак мочевого пузыря1. Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI: 10.1056/NEJMoa1613683. PMID: 28212060.Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI: 10.1056/NEJMoa1613683. PMID: 28212060.2. Witjes J.A., Bruins M., Compérat E. et al. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Pp. 1–78. Available at: http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/.Witjes J.A., Bruins M., Compérat E. et al. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Pp. 1–78. Available at: http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/.3. Powles T., Duran I., van der Heijdenet M.S. al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391(10122):748–57. DOI: 10.1016/S0140-6736(17)33297-X. PMID: 29268948.Powles T., Duran I., van der Heijdenet M.S. al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391(10122):748–57. DOI: 10.1016/S0140-6736(17)33297-X. PMID: 29268948.4. Birtle A., Johnson M., Kockelbergh R. et al. Results of POUT – a phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). European Urology Supplements. Vol. 17, Issue 2, e1431–e1432.Birtle A., Johnson M., Kockelbergh R. et al. Results of POUT – a phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). European Urology Supplements. Vol. 17, Issue 2, e1431–e1432.5. Motzer R.J., Tannir N.M., McDermott D.F. et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378(14):1277–90. DOI: 10.1056/NEJMoa1712126. PMID: 29562145.Motzer R.J., Tannir N.M., McDermott D.F. et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378(14):1277–90. DOI: 10.1056/NEJMoa1712126. PMID: 29562145.6. Ljungberg B., Albiges L., Bensalah K. et al. EAU Guidelines on Renal Cell Carcinoma. Pp. 1–70. Available at: http://uroweb.org/guideline/renal-cell-carcinoma/.Ljungberg B., Albiges L., Bensalah K. et al. EAU Guidelines on Renal Cell Carcinoma. Pp. 1–70. Available at: http://uroweb.org/guideline/renal-cell-carcinoma/.7. Lenis A.T., Donin N.M., Johnson D.C. et al. Adjuvant therapy for high risk localized kidney cancer: emerging evidence and future clinical trials. J Urol 2018;199(1): 43–52. DOI: 10.1016/j.juro.2017.04.092. PMID: 28479237.Lenis A.T., Donin N.M., Johnson D.C. et al. Adjuvant therapy for high risk localized kidney cancer: emerging evidence and future clinical trials. J Urol 2018;199(1): 43–52. DOI: 10.1016/j.juro.2017.04.092. PMID: 28479237.8. Ravaud A. Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC). Ann Oncol 2016;27:LBA1.Ravaud A. Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC). Ann Oncol 2016;27:LBA1.9. Motzer R.J., Haas N.B., Donskov F. et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 2017;35(35):3916–23. DOI: 10.1200/JCO.2017.73.5324. PMID: 28902533.Motzer R.J., Haas N.B., Donskov F. et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 2017;35(35):3916–23. DOI: 10.1200/JCO.2017.73.5324. PMID: 28902533.10. Fizazi K., Tran N., Fein L. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352–60. DOI: 10.1056/NEJMoa1704174. PMID: 28578607.Fizazi K., Tran N., Fein L. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352–60. DOI: 10.1056/NEJMoa1704174. PMID: 28578607.11. Edwards S.M., Kote-Jarai Z., Meitz J. et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003;72(1):1–12. PMID: 12474142.Edwards S.M., Kote-Jarai Z., Meitz J. et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003;72(1):1–12. PMID: 12474142.12. Agalliu I., Karlins E., Kwon E.M. et al. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer 2007;97(6):826– 31. DOI: 10.1038/sj.bjc.6603929. PMID: 17700570.Agalliu I., Karlins E., Kwon E.M. et al. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer 2007;97(6):826– 31. DOI: 10.1038/sj.bjc.6603929. PMID: 17700570.13. Castro E., Goh C., Olmos D. et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31(14):1748–57. DOI: 10.1200/JCO.2012.43.1882. PMID: 23569316.Castro E., Goh C., Olmos D. et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31(14):1748–57. DOI: 10.1200/JCO.2012.43.1882. PMID: 23569316.14. Kasivisvanathan V., Rannikko A.S., Borghi M. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018;378:1767–77. DOI: 10.1056/NEJMoa1801993. PMID: 29552975.Kasivisvanathan V., Rannikko A.S., Borghi M. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018;378:1767–77. DOI: 10.1056/NEJMoa1801993. PMID: 29552975.15. Bennett H.Y., Roberts M.J., Doi S.A., Gardiner R.A. The global burden of major infectious complications following prostate biopsy. Epidemiol Infect 2016;144(8):1784–91. DOI: 10.1017/S0950268815002885. PMID: 26645476.Bennett H.Y., Roberts M.J., Doi S.A., Gardiner R.A. The global burden of major infectious complications following prostate biopsy. Epidemiol Infect 2016;144(8):1784–91. DOI: 10.1017/S0950268815002885. PMID: 26645476.16. Eiber M., Herrmann K., Fendler W.P., Maurer T. et al. 68Ga-labeled prostate-specific membrane antigen positron emission tomography for prostate cancer imaging: the new kid on the block-early or too early to draw conclusions? Eur Urol 2016;70(6):938–40. DOI: 10.1016/j.eururo.2016.07.045. PMID: 27481174.Eiber M., Herrmann K., Fendler W.P., Maurer T. et al. 68Ga-labeled prostate-specific membrane antigen positron emission tomography for prostate cancer imaging: the new kid on the block-early or too early to draw conclusions? Eur Urol 2016;70(6):938–40. DOI: 10.1016/j.eururo.2016.07.045. PMID: 27481174.